Key points
- The BOD Australia share price is up nearly 7%
- The company’s announced a new trial on treatment for long term COVID-19
- It involves a medicinal cannabis product
The BOD Australia Ltd (ASX: BOD) share price is surging today amid news of a new COVID-19 clinical trial.
The company’s shares are currently swapping hands at 23.5 cents, up 6.82%.
Let’s take a look at what the company announced today?
Medicinal cannabis to treat COVID-19?
BOD investors are reacting to news of a clinical trial into the use of medicinal cannabis to treat long term COVID-19.
The company will work with Drug Science UK on the six-month trial featuring BOD’s flagship product MediCabilis.
Symptoms of long term COVID-19 include chronic pain, anxiety, fatigue, and sleeping trouble. The trial will recruit 30 people suffering from the condition.
BOD is hopeful it will be able to commercialise its product in the UK and “other countries” if the trial is successful.
About 1.3 million people are estimated to have long-COVID-19 in the UK with 1 in 40 of these having symptoms lasting three months or more.
BOD said its MediCabilis product is already prescribed to treat people with long-COVID-19 symptoms including anxiety, sleep disorders, and chronic pain.
Management comment
Speaking on the news of the trial, CEO Jo Patterson said:
While there aren’t any existing treatments for long-COVID, our medicinal cannabis products have been used to treat and alleviate a number of similar conditions.
We anticipate that this clinical trial will provide us with great insight into its potential to treat long-COVID and build on the body of evidence for the use of cannabis-based medicines, in place of other pharmaceuticals.
Share price snapshot
The BOD share price has crashed by 50% in the past year. Despite this, it is up 4% in the last month and nearly 7% in the past week.
In comparison, the S&P/ASX 200 Index (ASX: XJO) has returned more than 10% to investors in the past year.
The company commands a market capitalisation of about 24.9 million based on the current share price.
The post Why a COVID-19 trial is exciting BOD (ASX:BOD) investors today? appeared first on The Motley Fool Australia.
Should you invest $1,000 in BOD Australia right now?
Before you consider BOD Australia, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and BOD Australia wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- Here’s why the Adbri (ASX:ABC) share price is raging 8% higher today
- 2 ASX shares rated as strong buys by brokers
- Is this driving Santos (ASX:STO) and Woodside (ASX:WPL) shares higher on Monday?
- Here’s why the Kogan (ASX:KGN) share price is being sold off today
- Turning point? Magellan (ASX:MFG) posts market-beating fund returns for December
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3nvSyhE
Leave a Reply